Trial site
The First Affiliated Hospital of Henan University of Science &Technology
- 18running trials
- 8closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Conditions
- Obesity19 trials
- Type 2 diabetes14 trials
- High blood pressure3 trials
- Obstructive sleep apnoea2 trials
- Chronic kidney disease1 trial
- Chronic lymphocytic leukaemia1 trial
- Mantle cell lymphoma1 trial
- Peripheral artery disease1 trial
- Stroke1 trial
- Type 1 diabetes1 trial
- Phase
- Phase 324 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Completed7 trials
- Recruiting6 trials
- Not yet recruiting4 trials
- Withdrawn1 trial
- Lead sponsor
- Eli Lilly and Company26 trials
Running trials
Not yet recruiting
Not yet recruiting
Recruiting
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Recruiting
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Active, not recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Obesity8 recruiting
- Type 2 diabetes5 recruiting
- Chronic kidney disease1 recruiting
- Obstructive sleep apnoea1 recruiting
- Peripheral artery disease1 recruiting
- Stroke1 recruiting
Closed trials
Withdrawn
Completed
Completed
Completed
Completed
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Completed
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Completed
Completed
Site data: ClinicalTrials.govUpdated 19 Nov 2026